Literatur
-
1
Vincent J L, Bihari D J, Suter P M. et al .
The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.
JAMA.
1995;
274
639-644
-
2
Alberti C, Brun-Buisson C, Chevret S. et al .
European Sepsis Study Group. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients.
Am J Respir Crit Care Med.
2005;
171
461-468
-
3
Engel C, Brunkhorst F M, Bone H G. et al .
Epidemiology of sepsis in Germany: results from a national prospective multicenter study.
Intensive Care Med.
2007;
33
606-618
-
4
George D L, Falk P S, Wunderink R G. et al .
Epidemiology of ventilator acquired pneumonia based on protected bronchoscopic sampling.
Am J Respir Crit Care Med.
1998;
158
1839-1847
-
5
Garnacho-Montero J, Garcia Garmendia J L, Barrero-Almodovar A. et al .
Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.
Crit Care Med.
2003;
31
2742-2751
-
6
Cosgrove S E.
The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs.
Clin Infect Dis.
2006;
42 Suppl 2
82-89
-
7
Dietrich E S, Demmler M, Schulgen G. et al .
Nosocomial pneumonia: a cost-of-illness analysis.
Infection.
2002;
30
61-67
-
8
Mandell L A, Wunderink R G, Anzueto A. et al, American Thoracic Society .
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.
Clin Infect Dis.
2007;
44 Suppl 2
27-72
-
9
Estes R J, Meduri G U.
The pathogenesis of ventilator-associated pneumonia: mechanisms of bacterial translocation and airway inoculation.
Intensive Care Med.
1995;
21
365-383
-
10
Ewig S, Torres A, El-Ebiary M. et al .
Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia.
Am J Respir Crit Care Med.
1999;
159
188-198
-
11
Torres A, Carlet J. et al .
European Task force on ventilator associated pneumonia.
Eur Respir J.
2001;
17
1034-1045
-
12
Martin G S, Mannino D M, Eaton S, Moss M.
The epidemiology of sepsis in the United States from 1979 through 2000.
N Engl J Med.
2003;
348
1546-1554
-
13
el-Ebiary M, Torres A, Fabregas N. et al .
Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study.
Am J Respir Crit Care Med.
1997;
156
583-590
-
14
Meersseman W, Vandecasteele S J, Wilmer A. et al .
Invasive aspergillosis in critically ill patients without malignancy.
Am J Respir Crit Care Med.
2004;
170
621-625
-
15
National Nosocomial Infections Surveillance System .
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.
Am J Infect Control.
2004;
32
470-485
-
16
Huotari K, Tarkka E, Valtonen V, Kolho E.
Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli.
Eur J Clin Microbiol Infect Dis.
2003;
22
492-495
-
17
Hong T, Moland E S, Abdalhamid B. et al .
Escherichia coli: development of carbapenem resistance during therapy.
Clin Infect Dis.
2005;
40
e84-86
-
18
Neuhauser M M, Weinstein R A, Rydman R. et al .
Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.
JAMA.
2003;
289
885-888
-
19
Grundmann H, Barwolff S, Tami A. et al .
How many infections are caused by patient-to-patient transmission in intensive care units?.
Crit Care Med.
2005;
33
946-951
-
20
Goossens H, Ferech M, Vander Stichele R, Elseviers M.
Outpatient antibiotic use in Europe and association with resistance: a cross national database study.
Lancet.
2005;
365
579-587
-
21
Namias N, Samiian L, Nino D. et al .
Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies.
J Trauma.
2000;
49
638-645
-
22
Fagon J Y, Chastre J, Hance A J. et al .
Evaluation of clinical judgement in the identification and treatment of nosocomial pneumonia in ventilated patients.
Chest.
1993;
103
547-553
-
23
Wunderink R G, Woldenberg R S, Zeiss J. et al .
The radiologic diagnosis of autopsy-proved ventilator associated pneumonia.
Chest.
1992;
101
548-558
-
24
Welte T.
Die nosokomiale Pneumonie - State of the Art.
Intensivmedizin.
2006;
43
301-309
-
25
Kollef M H, Harz B Von, Prentice D. et al .
Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia.
Chest.
1997;
112
765-773
-
26
Fagon J Y, Chastre J, Wolff M. et al .
Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial.
Ann Intern Med.
2000;
132
621-630
-
27
Ruiz M, Torres A, Ewig S. et al .
Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome.
Am J Respir Crit Care Med.
2000;
162
119-125
-
28
Canadian Critical Care Trials Group .
A randomized trial of diagnostic techniques for ventilator-associated pneumonia.
N Engl J Med.
2006;
355
2619-2630
-
29
Maskell N A, Gleeson F V, Darby M. et al .
Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions.
Chest.
2004;
126
2022-2024
-
30
Welte T.
Ambulant erworbene und nosokomiale Pneumonie.
Internist.
2003;
44 Suppl 1
44-58
-
31
Pugin J, Auckenthaler R, Mili N. et al .
Diagnosis of ventilator-associated pneumonia by bacterologic analysis of bronchoscopic and nonbronchoscopic „blind” bronchoalveolar fluid.
Am Rev Respir Dis.
1991;
143
1121-1129
-
32
Harbarth S, Holeckova K, Froidevaux C. et al .
Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.
Am J Respir Crit Care Med.
2001;
164
396-402
-
33
Tang B M, Eslick G D, Craig J C, McLean A S.
Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.
Lancet Infect Dis.
2007;
7
210-217
-
34
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M M, Huber P R, Tamm M, Müller B.
Effect of procalcitonin guided treatment on antibiotic use and outcome in lower respiratory tract infections.
Lancet.
2004;
363
600-607
-
35
Krüger S, Ewig S, Marre R, Papassotriou J, Richter K, Baum H von, Suttorp N, Welte T. THE CAPNETZ STUDY GROUP .
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Eur Respir J .
2006;
EPub
-
36
Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D. et al .
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial.
Am J Respir Crit Care Med.
2006;
174
84-93
-
37
Ewig S, de Roux A, Bauer T. et al .
Validation of predictive rules and indices of severity for community acquired pneumonia.
Thorax.
2004;
59
421-427
-
38
Valles J, Rello J, Ochagavia A, Garnacho J, Alcala M A.
Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival.
Chest.
2003;
123
1615-1624
-
39
Trouillet J L, Chastre J, Vuagnat A. et al .
Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.
Am J Respir Crit Care Med.
1998;
157
531-539
-
40
American Thoracic Society; Infections Diseases Society of America .
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.
Am J Respir Crit Care Med.
2005;
171
388-416
-
41
Iregui M, Ward S, Sherman G, Fraser V J, Kollef M H.
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.
Chest.
2002;
122
262-268
-
42
Kumar A, Roberts D, Wood K E. et al .
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
Crit Care Med.
2006;
34
1589-1596
-
43
Sandiumenge A, Diaz E, Bodi M, Rello J.
Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of „The Tarragona Strategy”.
Intensive Care Med.
2003;
29
876-883
-
44
Shingh N, Roger P, Atwood C W, Wagener M M, Yu V L.
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Am J Respir Crit Care Med.
2000;
162
505-511
-
45
Chastre J, Wolff M, Fagon J Y. et al .
PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.
JAMA.
2003;
290
2588-2598
-
46
Giantsou E, Liratzopoulos N, Efraimidou E. et al .
Both early-onset and late-onset ventilator associated-pneumonia are caused mainly by potentially multiresistant bacteria.
Intensive Care Med.
2005;
31
1488-1494
-
47
Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L.
Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.
BMJ.
2004;
328
668
-
48
Safdar N, Handelsman J, Maki D G.
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.
Lancet Infect Dis.
2004;
4
519-527
-
49
Hoffman L R, D’Argenio D A, MacCross M J. et al .
Aminoglycoside antibiotics induce bacterial biofilm formation.
Nature.
2005;
436
1171-1175
-
50
Chamot E, Boffi El Amari E, Rohner P, Van Delden C.
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Antimicrob Agents Chemother.
2003;
47
2756-2764
-
51
Mayer I, Nagy E.
Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.
J Antimicrob Chemother.
1999;
43
651-657
-
52
Burkhardt O, Derendorf H, Welte T.
Neue Antibiotika für die Behandlung von MRSA-Infektionen.
Med Monatsschr Pharm.
2006;
29
56-62
-
53
Rello J, Sole-Violan J, Sa-Borges M. et al .
Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides.
Crit Care Med.
2005;
33
1983-1987
-
54
Silverman J A, Mortin L I, Vanpraagh A D, Li T, Adler J.
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.
J Infect Dis.
2005;
191
2149-2152
-
55
Falagas M E, Kasiakou S K, Kofteridis D P, Roditakis G, Samonis G.
Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.
Eur J Clin Microbiol Infect Dis.
2006;
25
596-599
-
56
Gruson D, Hilbert G, Vargas F. et al .
Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.
Crit Care Med.
2003;
31
1908-1914
-
57
van Loon H J, Vriens M R, Fluit A C. et al .
Antibiotic rotation and development of gram-negative antibiotic resistance.
Am J Respir Crit Care Med.
2005;
171
480-487
-
58
Bartlett J G.
Clinical practice. Antibiotic-associated diarrhea.
New Engl J Med.
2002;
346
334-339
Prof. Dr. Tobias Welte
Medizinische Hochschule Hannover
Abteilung Pneumologie
Carl Neuberg Straße 1
30625 Hannover
Phone: 0511/532-3530
Fax: 0511/532-3353
Email: Welte.Tobias@mh-hannover.de
